Clinical Trial

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

Study acronym: COAST
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-07-26; most recent amendment 2025-09-12.
Status change: Not Yet Recruiting → Recruiting 2024-11-06
Trial Details
NCT Number NCT06529406
Lead Sponsor University of Colorado, Denver
Conditions Relapsing Multiple Sclerosis
Enrollment 100 participants
Start Date 2024-07-29
Primary Completion 2028-08-01 (estimated)
Study Completion 2029-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-18